FORWARD PHARMA A/S: Financial statements 2012
CVR: 28865880
Source: annual report 2012, Danish Business Authority
01/01/2012 – 31/12/2012
FORWARD PHARMA A/S (CVR 28865880) has filed annual accounts for 2012. In 2012, the company reported a gross profit of DKK -10,966,924 and a net result of DKK 22,400,979. Equity in the 2012 report amounted to DKK 50,423,911. The solvency ratio was 77.6%.
- Gross Profit
- DKK -10,966,924
- Profit/Loss
- DKK 22,400,979
- Equity
- DKK 50,423,911
- Total Assets
- DKK 64,948,075
Keep an eye on FORWARD PHARMA A/S
Get notified instantly about new financial statements, ownership changes, management changes and status changes.
Set up monitoringEvents in 2012
As of December 8, 2012, John Kevin Buchi has joined the board of directors of FORWARD PHARMA A/S.
As of December 8, 2012, Hans Thalsgård Schambye has left the board of directors of FORWARD PHARMA A/S.
As of May 1, 2012, Peder Møller Andersen is registered as director of FORWARD PHARMA A/S.
As of April 30, 2012, Morten Priskorn has stepped down as director of FORWARD PHARMA A/S.
As of January 9, 2012, Florian Schønharting is registered as chairman of FORWARD PHARMA A/S.
As of January 9, 2012, Wyle David Solomon has stepped down as chairman of FORWARD PHARMA A/S.
About FORWARD PHARMA A/S
FORWARD PHARMA A/S was a Danish company of the type Aktieselskab based in Hellerup, founded in 2005 and dissolved in 2025. The company was registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The company has 4 employees (2018). In 2024, the company reported a gross profit of DKK -9,457,909 and a net result of DKK 75,927,645 compared with DKK -3,832,516 the year before. Equity in the 2024 report amounted to DKK 488,330,233.